Trevena EBIT/Assets

What does Trevena do? Trevena, Inc. develops and commercializes novel medicines for central nervous system disorders, focusing on OLINVO for moderate-to-severe acute pain management in hospitals and ambulatory surgery centers. The company commercializes OLINVO in the United States under its own brand, targeting healthcare providers in acute care settings. TRV250, a non-narcotic migraine treatment with potential for other CNS indications, is in Phase I development in the United Kingdom, with the company advancing its research through its ABLE product platform. Trevena leverages its ABLE platform to identify GPCR-targeted biased ligands, supporting its pipeline development without external partnerships or third-party sales. The company generates revenue through the commercialization of OLINVO in the U.S. acute care market, with healthcare facilities and providers as primary buyers. TRV250 remains in development, with no current sales, but the company anticipates future revenue once it progresses through clinical trials. Trevena’s ABLE platform serves as a foundational asset for discovering new compounds, reducing reliance on external licensing or collaborations. Its focus on G protein pathway selective modulators and biased ligands differentiates its product portfolio in CNS therapeutics. Trevena is one of the most popular companies on Eulerpool.